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Purpose. The purpose of this study was to demonstrate specific re-
ceptor-mediated targeting of phagocytes by functional surface coat-
ings of microparticles, shielding from nonspecific phagocytosis and
allowing ligand-specific interactions via molecular recognition.
Methods. Coatings of the comb polymer poly(L-lysine)-g-
poly(ethylene glycol) (PLL-g-PEG) were investigated for potential to
inhibit 1) nonspecific spreading of human blood-derived macro-
phages (MOs) and dendritic cells (DCs) on glass and 2) nonspecific
phagocytosis of PLL-g-PEG-coated, carboxylated polystyrene (PS)
or biodegradable poly(D,L-lactide-co-glycolide) (PLGA) micro-
spheres. Coating was performed by adsorption of positively charged
PLL-g-PEG on negatively charged microparticles or plasma-cleaned
glass through electrostatic interaction. The feasibility of ligand-
specific interactions was tested with a model ligand, RGD, conju-
gated to PEG chains of PLL-g-PEG to form PLL-g-PEG-RGD and
compared with inactive ligand conjugate, PLL-g-PEG-RDG.
Results. Coatings with PLL-g-PEG largely impaired the adherence
and spreading of MOs and DCs on glass. The repellent character of
PLL-g-PEG coatings drastically reduced phagocytosis of coated PS
and PLGA microparticles to 10% in presence of serum. With both
MOs and DCs, we observed ligand-specific interactions with PLL-g-
PEG-RGD coatings on glass and PS and PLGA microspheres. Li-
gand specificity was abolished when using inactive ligand conjugate
PLL-g-PEG-RDG, whereas repellency of coating was maintained.
Conclusions. Coatings of PLL-g-PEG-ligand conjugates provide a
novel technology for ligand specific targeting of microspheres to MOs
and DCs while reducing nonspecific phagocytosis.
KEY WORDS: poly(D,L,-lactide-co-glycolide) (PLGA) micro-
spheres; surface modification; poly(L-lysine)-grafted-poly(ethylene
glycol) (PLL-g-PEG); phagocytosis; RGD-peptide.
INTRODUCTION
For almost two decades injectable, biodegradable micro-
spheres have been developed into an established platform for
the sustained delivery of therapeutics for localized or systemic
action. After injection of such microspheres, the embodied
drugs can be protected from proteolytic cleavage and follow a
controlled and prolonged release regimen that is governed by
the bioerosion of the polymer carrier. Particularly, micro-
spheres prepared from poly(D,L-lactide-co-glycolic acid)
(PLGA) have a proven track record for drug delivery. They
are highly biocompatible and biodegradable, and their rates
of bioerosion and release of encapsulated drugs can be tai-
lored by modulating their composition (1,2). This makes the
microencapsulation of drugs in PLGA microspheres an ap-
proved and safe technology for the long term delivery of
therapeutics.
Phagocytic cells, such as macrophages (MOs), may rec-
ognize injected particulate drug carriers as foreign materials
and remove them quickly and efficiently via nonspecific
phagocytosis by the mononuclear phagocytic system (MPS).
The MPS represents a main hurdle that needs to be overcome
to achieve selective targeting of particulates to selected or-
gans, tissues, or cells. The phagocytosis of microspheres is
stimulated by their surface properties and is believed to be
enhanced by charged or hydrophobic surfaces (3). Further-
more, the extent of phagocytosis is enhanced by the adsorp-
tion of opsonic plasma proteins to their surface (4). To protect
particulates from phagocytosis, poly(ethylene glycol) (PEG)
coatings have been investigated for a wide array of biomedi-
cal applications. Immobilization of PEG on surfaces has long
been known to decrease protein adsorption (5,6). Approaches
to immobilize PEG on the surface of microspheres involve
covalent grafting (7–9), or adsorption of PEG-containing
nonionic surfactants, such as poloxamers, through hydropho-
bic interaction (10,11). Such approaches not only reduce
plasma protein adsorption, but also inhibit the nonspecific
uptake by phagocytes (5,8,10,12).
Nevertheless, upon uptake of water, adsorbed nonionic
surfactants may quickly desorb from the surface, especially
when microspheres were prepared from fast biodegrading,
low molecular weight PLGA polymers (13). However, the
chemical derivatization of PLGA is restricted to the end
groups of the polymer chain and therefore likely to affect the
physicochemical and bioerosion characteristics of the poly-
mer. This renders the development of drug-loaded micro-
spheres from modified PLGA more complex because it re-
quires case-to-case adjustments of composition and process
parameters for microencapsulation. To avoid this complexity,
surface coatings of PLGA microspheres would be highly de-
sirable to modify their biodistribution and reduce their physi-
ologic clearance by the MPS.
Recently, a new class of grafted comb copolymers based
on poly(L-lysine)-g-poly(ethylene glycol) (PLL-g-PEG) was
found to spontaneously adsorb from aqueous solution onto
several metal oxide surfaces and onto heterogeneous biologic
surfaces (6,14). The architecture of the comb copolymer has
been demonstrated to play an important role for its behavior.
When adjusted accordingly, the resulting adsorbed layers are
highly effective in reducing the adsorption of plasma proteins.
Adsorptive immobilization of the protective PEG-moiety is
suggested to occur through interaction of the positively
charged primary amino groups of PLL bound to the nega-
tively charged surface (6,14).
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PLGA microspheres display a hydrophobic and at the
same time highly negatively charged surface (15,16). They
have been demonstrated to be subject to extensive plasma
protein adsorption (12) and are efficiently phagocytosed by
the MPS, and by antigen presenting cells like MOs and den-
dritic cells (DCs) (15).
At first, this work aim to investigated the potential of a
protein-repellant, PLL-g-PEG-based surface coating to pre-
vent the nonspecific uptake of PLGA microspheres by phago-
cytic cells. For this purpose, we studied the uptake of model
polystyrene (PS) and PLGA microspheres by human-derived
peripheral blood MOs and DCs, upon coating the micro-
spheres with PLL-g-PEG. As a second step, we investigated
the effect of a model peptide ligand, RGD (17), grafted to
PLL-g-PEG, on the receptor-mediated phagocytosis of suit-
ably coated microspheres by MOs and DCs. The RGD motif
serves as a model ligand for the specific interaction of the
coatings with integrin receptors, which are expressed on the
surface of phagocytic cells. Thus, our study represents a
proof-of-concept to demonstrate that specific, receptor-
mediated recognition between suitably coated microspheres
and phagocytes is feasible. Provided that selective phagocyte
specific ligands can be identified, the microspheres would
have potential, e.g., as a platform for the specific targeting of
particulate vaccine delivery systems to professional antigen-
presenting cells, such as DCs.
MATERIALS AND METHODS
Materials
Carboxylated PS that were 4.5 m in diameter and car-
ried a negative charge were obtained from Polysciences Eu-
rope, Basel, Switzerland. PLGA-type polymer (Resomer
RG502H, ratio lactide:glycolide 50:50, molecular weight
14,000, uncapped end groups) was obtained from Boehringer
Ingelheim (Germany). The PLL-g-PEG polymer used in this
study consisted of a PLL-backbone of 20 kDa with grafted
PEG chains of 2 kDa and a grafting ratio of lysine units to
PEG side chains of 3.3 (6). Further modification of this poly-
mer was by conjugation with the RGD adhesion motif to yield
PLL-g-PEG-RGD, and RDG as negative control for PLL-g-
PEG-RDG, both with an approximate peptide coverage of
0.1 pmole/cm2 (17). All PLL-g-PEG polymers were synthe-
sized as outlined by Huang et al. (18). All chemicals used in
this study were of analytical grade (from Fluka, Switzerland)
unless otherwise specified.
Methods
PLGA Microspheres
PLGA microspheres were prepared by spray drying as
previously described (19). Briefly, PLGA-type polymer was
dissolved in dichloromethane (w/w 5%) and was spray-dried
in a laboratory spray-dryer (Model 190, Bu¨chi, Switzerland)
at an inlet temperature of 45°C. The spray-flow was set at 500
NL/h and the product feed was 3 ml/min. The microspheres
were washed with water, collected on a 0.45-m cellulose
acetate membrane filter and dried under vacuum for 24 h.
The microspheres were stored at 4°C. Fluorescence-labeled
PLGA microspheres were prepared by adding 6-coumarine (5
mg/g polymer, Acros Organics, Belgium) to the polymer so-
lution. Size distribution of the microspheres was measured by
laser light scattering (Mastersizer X, Malvern Instruments
Ltd., Worcestershire, UK; equipped with a 45-mm lens). Cal-
culation of particles size and distribution was based on Mie’s
theory. The particle size distribution was presented in the
volume-weighted mode and revealed particles in the range of
1–10 m as previously described in detail (15,19).
MO and DC Cell Culture
MOs and DCs were obtained from human peripheral
blood monocytes according to Sallusto et al. (20). Briefly,
peripheral blood monocytes were isolated from buffy coats
(Bloodbank Zurich, Switzerland) by density gradient cen-
trifugation of Ficoll-Paque (Pharmacia Biotech, Buchs, Swit-
zerland). Peripheral blood monocytes were resuspended in
RPMI 1640 supplemented with 10% heat-inactivated
(pooled) human serum (Bloodbank Zu¨rich, Switzerland) and
then allowed to adhere for 2 h in culture flasks (25 cm2).
Nonadherent cells were removed and adherent cells were fur-
ther cultured in RPMI 1640 supplemented with 5% heat-
inactivated (pooled) human serum in the presence of 1000
IU/mL interleukin-4 (Sigma, Switzerland) and 50 ng/mL
granulocyte macrophage-colony stimulating factor (R+D Sys-
tems) to obtain DCs. MOs were obtained without additional
supplements (21). Cultures of MOs and DCs were kept at
37°C in 5% CO2-humidified atmosphere. For particle uptake
studies, cells were mechanically removed from the flasks after
24 h and reseeded onto coverslips in 24-well plates (300,000–
400,000 cells per well) for further studies.
Surface antigen expression of MOs and DCs was ana-
lyzed by flow cytometry (22). For further identification, the
cells were also challenged with lipopolysaccharide (1 g/mL,
Escherichia coli 055:B5, Sigma) 48 h before the antibody la-
beling, which causes maturation of DCs only. The cells were
incubated (45 min, 4°C) with each of the following primary
anti-human antibodies: CD11b (Mac-1, ICRF44; 44), CD83
(Clone HB15e), CD86 (B70/B7-2, Clone IT2.2; all three from
Pharmingen, Lucerne, Switzerland), and CD14 (Clone
UCHM-1, Sigma). Control cells were processed similarly with
mouse isotype control IgG2a (UPC-10, Sigma). Cells were
washed three times and subsequently incubated with the sec-
ondary antibody (anti-mouse IgG, R-Phycoerythrin conju-
gated, Sigma) for 45 min at 4°C, washed three times, trans-
ferred to FACS tubes, and analyzed on an FACScan type
from Becton Dickinson (Switzerland). According to these cri-
teria, more than 90% of the cells were identified as DCs, and
in MOs cultures more than 90% of the cells were CD14+ and
CD83−, even in the presence of lipopolysaccharide.
Adhesion Studies
The adhesion of MO and DC on modified surfaces was
first tested on glass surfaces coated with PLL-g-PEG and
PLL-g-PEG-RGD or PLL-g-PEG-RDG, respectively. Before
coating, the glass coverslips (12 mm in diameter) were oxy-
gen-plasma cleaned in a Plasma Cleaner/Sterilizer PDC-32G
instrument (Harrick Scientific Corporation, Ossining, NY)
for 7 min. Coating was performed in 24-well plates under
aseptic conditions with 1 mg/mL of the respective polymers
dissolved in 10 mM HEPES buffer, pH 7.4, for 15 min. All
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solutions were filtered through a 0.2-m membrane filter be-
fore use. Control coverslips were incubated in HEPES buffer
only. After coating, the coverslips were rinsed twice for 5 min
with phosphate-buffered saline (PBS) and once with RPMI
1640 medium. MOs or DCs incubated for 1 week in cell cul-
ture flasks were added to each well (250,000 cells in 600 L of
cell medium) containing either coated or control coverslips
and cell adhesion was checked after different time points by
microscopy (Axiovert 35, Zeiss, Germany). Images were
taken using a CCD camera (CF 8/1 DXC, Kappa, Gleichen,
Germany).
Coating of Microspheres
Microspheres were dispersed in filtered HEPES buffer at
a concentration of 5 mg/mL (polystyrene particles) or 1 mg/
mL (PLGA microspheres). The dispersions were mixed at
equal volumes with PLL-g-PEG, PLL-g-PEG-RGD or PLL-
g-PEG-RDG (1 mg/mL in filtered HEPES buffer) and incu-
bated under gentle mixing for 15 min at room temperature.
The coated microspheres were centrifuged (5 min, 7,400 × g,
Eppendorf, Centrifuge 5417R, Eppendorf-Netheler-Hinz
GmbH, Germany) and redispersed in half of the previous
volume in filtered HEPES buffer by slightly vortexing.
Phagocytosis Studies
MOs cultured on coverslips in 24-well plates were
washed once with RPMI 1640 medium and then covered with
1 mL of RPMI 1640 medium with or without serum. Micro-
spheres dispersed in HEPES buffer were added and the cells
were incubated at either 37°C or at 4°C for 4 h. The cells were
washed twice with RPMI 1640 medium and subsequently
fixed with 3% paraformaldehyde in PBS for 30 min at room
temperature. The samples were stored in PBS at 4°C. Because
DCs only slightly adhered to the cell culture plates or to
coverslips, these cells were not washed and the microspheres
were added directly to the cells. Also the washing step after
incubation was avoided and approximately 300 L of medium
was added to each well to allow a better verification of phago-
cytosed microspheres. These samples were analyzed immedi-
ately without prior fixation.
Sample Analysis by Fluorescence Microscopy
The amount of phagocytosed microspheres per cell was
assessed by fluorescence microscopy (Axiovert 35, Zeiss,
Germany; filter set: excitation 450–490/emission 520, beam-
splitter 510). A minimum of three samples was checked per
experiment and the number of microspheres taken up per cell
was counted in 50 cells per sample. Images were taken using
a CCD camera (CF 8/1 DXC, Kappa, Gleichen, Germany).
To assure cell viability some of the samples were stained with
ethidium bromide homodimer-1 (EthD1, 2 L/mL, Molecular
Probes, Lucerne, Switzerland) in PBS for 30 min at room
temperature (250 L/well). Viability staining was performed
before fixing the cells. Cellular uptake of EthD1 is restricted
to nonviable, necrotic cells with leaky cell membranes. Stain-
ing results from nuclear intercalation with DNA. Necrotic
cells were detected by fluorescence microscopy (Axiovert 35,
Zeiss, Germany; excitation 546/emission 590, beam splitter
580).
Sample Analysis by Confocal Laser Scanning
Microscopy (CLSM)
For CLSM, the cells were stained with rhodamine-
labeled phalloidine (tetramethylrhodamine isothiocyanate-
phalloidine, Sigma) to visualize the actin cytoskeleton of the
cells. All incubation steps were performed at room tempera-
ture. After fixation, the cells were incubated in 0.1 M glycin in
PBS for 5 min. The samples were washed once with PBS,
incubated for 40 min with 0.2% Triton X-100 to permeabilize
the cell membrane, and then washed once again with PBS.
Rhodamine-phalloidine, diluted 1:10 in 3% BSA (bovine se-
rum albumin) in PBS, was added and samples were incubated
for 90 min in the dark. The samples were washed three times
for 5 min with PBS and subsequently mounted on coverslips
for microscopic evaluation using a Zeiss LSM 510 (Zurich,
Switzerland; lasers He-Ne 543 nm, Ar 488/514 nm).
Significance Testing
The significance of the results was tested using a t test
(assuming unequal variances).
RESULTS AND DISCUSSION
Inhibition of Cellular Interactions by PLL-g-PEG-Modified
Flat Surfaces
In earlier investigations, the comb polymer system PLL-
g-PEG has been demonstrated to be highly efficient in reduc-
ing the adsorption of serum proteins on flat metal oxide sur-
faces (6,18). PLL-g-PEG consists of a PLL backbone, which is
highly cationic at a physiologic pH, and spontaneously ad-
sorbs from aqueous solutions onto negatively charged sur-
faces by electrostatic interactions (6). At high grafting den-
sity, the PEG chains form a densely packed brush, providing
the protein-resistant function of the graft. This performance
was found to depend on the molecular weight of the PEG
chains, the grafting ratio of the PLL-g-PEG copolymer, and
the surface coverage of the polymer (6,14,18). Based on pre-
vious results (6), we used a PLL backbone of 20 kDa with
grafted PEG chains of 2 kDa and a molar grafting ratio of Lys
units to PEG side chains of 3.3.
To test the repellent effect of PLL-g-PEG on profes-
sional phagocytic cells, MO and DC, we coated glass surfaces
with PLL-g-PEG and tested the adhesion of the cells in com-
parison with untreated glass. All samples were checked by
microscopy after 1, 4, 24 and 48 h. After only 4 h, we observed
a clear difference between untreated glass and PLL-g-PEG-
coated glass. Adhesion appeared to be complete after 24 h.
Both cell types displayed high affinity to untreated glass, as
indicated by significant cell adhesion and spreading (Fig. 1a,
e). In contrast, PLL-g-PEG treatment completely abolished
cellular adhesion and spreading, with the remaining cells typi-
cally adopting a spherical cross-section at a reduced diameter
(Fig. 1 b, f). Thus, in addition to their protein-repellent char-
acter, PLL-g-PEG coatings limited the biologic interactions
and recognition of the surfaces by professional phagocytes.
Ligand-Specific Interactions by PLL-g-PEG-RGD-Modified
Flat Surfaces
The next aim was to convert the repellent surface to an
interface with specific bioreactivity, while maintaining its re-
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pellent characteristic toward nonspecific interactions. PLL-g-
PEG was modified at the terminal position of the PEG chains
to provide additional reactive sites for the specific interaction
with cellular surfaces or cellular receptors. As a model ligand,
we used an RGD-containing peptide that has been suggested
to mediate receptor specific interactions with MOs and DCs
because of its affinity to integrin receptors expressed on the
surface of these cells (23–25). The RGD-containing peptide
was covalently bound to the PEG chains (PLL-g-PEG-RGD;
17) with an approximate coverage of 0.1 pmol/cm2. We found
ligand-specific adhesion and spreading of the cells after coat-
ing the glass surface with PLL-g-PEG-RGD (Fig. 1c, g). In
contrast, coating with PLL-g-PEG conjugated to the inactive
control RDG peptide (PLL-g-PEG-RDG) resulted in the
same repellent character as PLL-g-PEG (Fig. 1d, h), support-
ing the ligand-specific character of the interaction with PLL-
g-PEG-RGD. The data demonstrate that the PLL-g-PEG sys-
tem can be used as a platform to generate surfaces displaying
Fig. 1. Adhesion and spreading of macrophages (a–d) and dendritic cells (e–h) on untreated glass surfaces (a,
e), and on glass surfaces coated either with PLL-g-PEG (b, f), PLL-g-PEG-RGD (c, g), or PLL-g-PEG-RDG
(d, h). Photographs were taken after 24 h of incubation.
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a selective interaction with specific cellular binding sites on a
highly protein-resistant background.
Inhibition of Nonspecific Phagocytosis by Surface
Modification with PLL-g-PEG
Intensive investigations have been undertaken to inhibit
nonspecific uptake of polymeric micro- and nanospheres by
phagocytic cells of the MPS. Polystyrene particles were pre-
viously used as model systems and were either coated with
nonionic surfactants by hydrophobic interaction, such as poly-
mers of the poloxamer and poloxamine series (10,11,26) or
were made of polystyrene covalently linked to PEG chains
(7), resulting in bulk modified microspheres exposing a repel-
lent surface. All approaches resulted in the inhibition of
phagocytosis down to 20–35% in the presence of serum.
Moreover, experiments in vivo demonstrated that coatings
with hydrophilic surfactants such as PEG, poloxamers, polox-
amines or poly(vinylalcohol) indeed prolong significantly the
circulation time and alter the body distribution of synthetic
carriers (27–31).
To investigate the phagocytosis-inhibiting effect of PLL-
g-PEG coatings, we used carboxylated polystyrene particles
with a particles size of 4.5 m, which were previously re-
ported to be efficiently phagocytosed by MOs and DCs (21).
Because they exhibit a negative surface charge (21), they were
expected to be efficiently coated by the positively charged
PLL-g-PEG polymer because of electrostatic interactions.
We analyzed by microscopic examination the uptake of non-
coated and PLL-g-PEG-coated polystyrene particles in MOs
and DCs. A typical photomicrograph is given in Fig. 2. No
particle uptake was detected when the incubation was per-
formed at 4°C. Different amounts of particles were added to
the cells (2 × 106, 107, 2 × 107, 4 × 107 particles/well) and
saturation was obtained with 107 particles/well which corre-
sponds to an average of approximately 25 particles per cell
(data not shown). Thus, throughout we performed further
experiments by adding 107 particles/well. A typical distribu-
tion of internalized particles per cell is shown in Fig. 3a. Be-
cause of its broad statistical distribution, the data was pre-
sented as box plots (Fig. 3b and c).
Coatings of the microspheres with PLL-g-PEG effi-
ciently reduced phagocytosis by MOs and DCs (p  0.05) to
about 10% of the average number of phagocytosed particles
observed with noncoated particles (Fig. 3). The repellent
character of the PLL-g-PEG coating was maintained up to 4
d at either 4 or 37°C and was independent of the presence of
serum proteins (data not shown). Thus, inhibition of phago-
cytosis by PLL-g-PEG coatings due to electrostatic interac-
tions was comparable or even superior to coatings consisting
of nonionic surfactants (10,11,26). Our data thus suggests that
the repellent character of PLL-g-PEG surface coatings may
be maintained for a relevant time span that might be suffi-
cient to significantly alter the body distribution of the micro-
spheres and enhance their circulation time in vivo. Such ex-
periments are considered for future studies.
Induction of Specific Phagocytosis by Surface Modification
with PLL-g-PEG-RGD
Targeted delivery of micro- and nanospheres to a se-
lected tissue or a specific receptor has raised increasing inter-
est for the administration of potent drugs (32–40). In addition,
addressing a specific receptor may induce distinct signaling
pathways in the target cells, such as in immunomodulatory
antigen-presenting cells (23,41–44). To avoid other pathways,
nonspecific phagocytosis needs to be limited at the same time
in order to enable specific interactions with the target tissue
or the selected receptor. In accordance with the experiments
with flat glass surfaces, we aimed to convert the PLL-g-PEG-
coated repellent particle surface to an interface with specific
bioreactivity, while maintaining its repellence toward nonspe-
cific phagocytosis. Indeed, coating of the polystyrene particles
with PLL-g-PEG-RGD fully abolished the repellent nature of
the particles and led to ligand-specific phagocytosis. In con-
trast, no bioreactivity was observed when the inactive RDG
peptide was conjugated to the polymer (p  0.05; Fig. 3).
Coatings of inactive RDG modified PLL-g-PEG were equally
repellent as PLL-g-PEG coatings.
Phagocytosis of Surface-Modified PLGA Microspheres by
MOs and DCs
Whereas polystyrene particles were only used as model
particles, microspheres prepared from biodegradable PLGA
are pharmaceutically more meaningful. They have been ex-
tensively studied for the encapsulation and delivery of thera-
peutics, and were successfully marketed for human use (2,45).
PLGA microspheres prepared by spray-drying were previ-
ously reported to be in the size range of 1–10 m and to
display a strongly negative surface charge (16). In another
study, we confirmed the feasibility to achieve stable PLL-g-
PEG coatings on the surface of PLGA microspheres by sim-
ply incubating the microparticles in an aqueous solution of
PLL-g-PEG (46). Moreover, PLL-g-PEG-coated PLGA mi-
crospheres showed a drastic decrease in protein adsorption by
two orders of magnitude in comparison to noncoated micro-
spheres due to the high surface density of PEG chains corre-
sponding to 15–25 ethylene-glycol monomers per nm2 (46).
In accordance with the studies with polystyrene particles,
we analyzed the uptake of noncoated and PLL-g-PEG-coated
fluorescent-labeled PLGA microspheres in MOs and DCs by
microscopic examination. Again, no uptake was seen when
the incubation was performed at 4°C. Different amounts of
particles added to the cells (20, 100, 200, and 400 of g mi-
crospheres per well) indicated saturation at about 100 g mi-
crospheres per well. Thus, all further experiments were per-
formed at 100 g microspheres per well. In correspondence
with the data on polystyrene particles, coating of the PLGA
microspheres with PLL-g-PEG significantly reduced phago-
cytosis by MO and DC (Fig. 4) to about 10% of the values
with noncoated particles.
Phagocytosis of noncoated and PLL-g-PEG-coated
PLGA microspheres was further investigated by CLSM to
verify the intracellular localization of the microspheres in
contrast to those attached to the outer membrane. The shape
of the phagocytes was visualized by staining their actin cyto-
skeleton with rhodamine-phalloidine (red), while the micro-
spheres were labeled with 6-coumarin (green; Fig. 5). The
result is a clear difference between the phagocytosis of non-
coated vs. PLL-g-PEG-coated PLGA microspheres. Quanti-
fication of uptake by counting the number of microspheres in
the cells resulted in numbers, which were in reasonable agree-
ment with the data obtained by fluorescence microscopy
(data not shown).
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A preliminary estimation of the cellular toxicity of the
coatings was also performed. In control experiments, less than
5% of the MOs or DCs were found to be necrotic, irrespective
of whether noncoated or PLL-g-PEG-coated microspheres
were used. This corresponds to previous investigations on
toxicity (14), immunogenicity, immunomodulatory potential,
pyrogenicity and biodegradation (47–49) of PLL-g-PEG and
suggests good biocompatibility of the coatings.
Previous attempts to inhibit phagocytosis of PLGA and
poly(L-lactide) (PLA) micro- and nanospheres by surface
modification focused on coatings with poloxamer (11), high
molecular weight PEG (50), or on the use of di-block and
tri-block co-polymers of PLA/PLGA and PEG to prepare
bulk modified micro- or nanospheres (8,9,51). For instance,
the circulation time of PLA-PEG nanospheres was extended
up to 6 h and they were found in increasing amounts in the
heart, in blood vessels and in the lung (52). Inhibition of
phagocytosis in the presence of serum or plasma was down to
Fig. 2. Phagocytosis of polystyrene particles by macrophages (a–d) and dendritic cells (e–h) upon the addition
of noncoated particles (a, e), and particles coated with PLL-g-PEG (b, f), PLL-g-PEG-RGD (c, g), and
PLL-g-PEG-RDG (d, h). Photographs were taken after 4 h of incubation at 37°C.
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20–55%, revealing a comparable or even superior effect of
the PLL-g-PEG-coated microspheres used in this study.
Moreover, at both 4 and 37°C the repellent character of the
PLL-g-PEG coatings on PLGA microspheres was maintained
for up to 4 days (data not shown). In contrast, when in contact
with water, the coatings of nonionic surfactants are subject to
enhanced desorption followed by water uptake and subse-
quent swelling, especially with microspheres prepared from
fast degrading low molecular weight PLGA polymers (13).
From a fabrication point of view, the spontaneous adsorption
of PLL-g-PEG polymers to the carriers appears to be a su-
perior technology to the covalent PEGylation of the polymer
bulk. The combination of two separate platforms, i.e., the
established PLGA microsphere technology and the PLL-g-
PEG based surface modification, may allow separate devel-
opment and optimization of carrier and coating. Conversely,
the use of PEG-modified bulk polymers is expected to affect
the physicochemical properties and the bioerosion of the
polymer matrix, and requires the composition and process
parameters for microencapsulation to be optimized on a case-
to-case basis.
In addition to the inhibition of nonspecific phagocytosis
and in correspondence with the data from polystyrene par-
ticles, we found that coatings of the PLGA microspheres with
PLL-g-PEG-RGD resulted in ligand-specific phagocytosis by
MO and DC (Fig. 4). As compared with noncoated micro-
spheres the extent of phagocytosis of PLL-g-PEG-RGD-
coated microspheres was decreased, which may be explained
by some degree of microsphere agglomeration observed
in the preparation. To our knowledge, this is the first dem-
onstration of a technology that enables the targeting of
biodegradable PLGA microspheres to specific cell surface re-
ceptors while simultaneously preventing nonspecific phago-
cytosis.
CONCLUSIONS
In this study, we demonstrated a simple and reproducible
approach for the surface modification of biodegradable
PLGA microspheres for targeting purposes. Coating with
positively charged PLL-g-PEG by electrostatic interaction
with negatively charged microspheres drastically reduced the
nonspecific uptake by professional phagocytes such as MO
and DC. Conjugation of a specific ligand to PLL-g-PEG en-
ables receptor-specific targeting while maintaining the repel-
lent character of PLL-g-PEG coatings. This should preclude
rapid physiologic clearance of the microparticles by the MPS.
The biospecificity of the interaction was proven by using the
inactive nonspecific RDG-conjugated polymer as a control.
Overall, our findings provide a potential technology to dimin-
ish nonspecific phagocytosis of micro- and nanoparticles and
Fig. 3. Phagocytosis by macrophages (MOs) and dendritic cells
(DCs). Typical distribution (a) showing the uptake of noncoated and
PLL-g-PEG-coated polystyrene particles in MOs. Box plots for the
phagocytosis by MOs (b) and DC (c) of noncoated particles and
particles coated with either PLL-g-PEG, PLL-g-PEG-RGD, or PLL-
g-PEG-RDG. Significance testing revealed differences between non-
coated and PLL-g-PEG-coated particles (p  0.05) and between
PLL-g-PEG-RGD- and PLL-g-PEG-RDG-coated particles (p 
0.05) for both MOs and DCs.
Fig. 4. Phagocytosis of noncoated PLGA microspheres and micro-
spheres coated with either PLL-g-PEG, PLL-g-PEG-RGD, or PLL-
g-PEG-RDG by macrophages (a) and dendritic cells (b) presented as
box plots. Significance testing revealed differences between non-
coated and PLL-g-PEG-coated particles (p  0.05) and between
PLL-g-PEG-RGD- and PLL-g-PEG-RDG-coated particles (p 
0.05) for both macrophages and dendritic cells.
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Fig. 5. Phagocytosis of noncoated (a) and PLL-g-PEG-coated (b) PLGA microspheres in macrophages as analyzed by confocal laser scanning
microscopy. The outline of the individual cells was visualized by staining the actin cytoskeleton with rhodamine-phalloidin (red). Microspheres
were labeled with 6-coumarin (green). Optical sections (xy, left panel) and yz-projections (right panel) allow to distinguish between extra-
cellular and internalized microspheres.
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at the same time target them to specific receptors. As a proof-
of-concept this study was restricted to a model ligand, RGD.
For the future we expect larger benefit of this novel technol-
ogy to result from the use of more selective ligands, e.g., for
the specific targeting of DC rather than MO (53). Moreover,
in case suitable ligands can be provided, the technology may
be also of use to target particulate drug carriers to other
tissues and cells. This needs yet to be demonstrated by ex-
periment.
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